Korean Stock Flows

Celltrion (KRX: 068270)

셀트리온 KOSPI Biotech & Pharma 기초 의약물질 제조업
Close (Oct 13, 2026)
₩179,700
-0.39%
Market cap
₩42T ($31.4B)
52-week range
₩158,500 – ₩239,245
P/E (12M fwd) · P/B · Div yield
24.30 · 2.40 · 0.42%
trailing 40.39 · consensus of 22 analysts

Who is buying Celltrion?

Between Sep 10, 2026 and Oct 13, 2026 (20 trading sessions), foreign investors net bought ₩30.4bn ($23M) of Celltrion, the 25th largest foreign net purchase among 832 KOSPI stocks. Institutions net sold ₩81.6bn ($61M) and retail investors net sold ₩59.5bn ($45M) over the same window. Foreigners were net buyers on 10 of the 20 sessions.

Foreign investors hold 25.29% of Celltrion's listed shares (KRX ownership data as of Oct 13, 2026), up from 25.25% twenty sessions earlier and 21.26% a year ago.

The stock closed at ₩179,700 on Oct 13, 2026: -1.86% over 20 sessions, +4.16% year-to-date, +10.32% over one year. The 52-week range is ₩158,500 – ₩239,245.

At ₩179,700 the stock trades at 24.30× 12-month-forward consensus earnings (22 analysts), 23.55× on FY2027 estimates. The trailing P/E published by KRX is 40.39×, based on the last completed fiscal year.

Celltrion share price, last 60 trading days (KRW)
212,924 197,841 182,759 167,676 Jul 13 Aug 26 Oct 13
Daily foreign investor net purchases, last 60 trading days
+132.4bn +66.2bn -66.2bn -132.4bn Jul 13 Aug 26 Oct 13
View chart data as a table
Date Close Foreign net Institutions Retail
2026-10-13 ₩179,700 ₩-4.8bn +₩19.0bn ₩-23.0bn
2026-10-12 ₩180,400 ₩-14.2bn +₩15.9bn ₩-11.0bn
2026-10-08 ₩179,600 +₩10.7bn ₩-22.7bn +₩3.2bn
2026-10-07 ₩183,500 +₩6.3bn ₩-3.1bn ₩-11.9bn
2026-10-06 ₩182,400 ₩-9.4bn +₩1.4bn ₩-0.9bn
2026-10-02 ₩182,600 ₩-14.6bn +₩1.9bn +₩3.4bn
2026-10-01 ₩183,600 +₩27.2bn +₩11.4bn ₩-48.0bn
2026-09-30 ₩177,700 ₩-8.1bn ₩-6.4bn +₩3.6bn
2026-09-29 ₩178,900 +₩1.4bn ₩-2.5bn +₩0.9bn
2026-09-28 ₩178,300 +₩9.1bn +₩0.3bn ₩-9.7bn
2026-09-23 ₩177,400 +₩0.5bn ₩-0.1bn ₩-0.5bn
2026-09-22 ₩178,500 ₩-15.5bn ₩-4.6bn +₩19.4bn
2026-09-21 ₩181,400 +₩0.3bn +₩9.6bn ₩-9.3bn
2026-09-18 ₩179,400 ₩-11.1bn +₩4.1bn +₩7.3bn
2026-09-17 ₩180,300 ₩-4.4bn +₩19.7bn ₩-14.9bn
2026-09-16 ₩177,200 ₩-20.7bn +₩8.6bn +₩12.3bn
2026-09-15 ₩177,500 ₩-0.4bn ₩-4.4bn +₩4.9bn
2026-09-14 ₩178,800 +₩12.8bn ₩-15.8bn ₩-11.8bn
2026-09-11 ₩178,200 +₩28.5bn ₩-53.2bn +₩14.2bn
2026-09-10 ₩180,800 +₩36.8bn ₩-60.9bn +₩12.4bn
2026-09-09 ₩183,100 +₩0.9bn ₩-8.1bn ₩-3.6bn
2026-09-08 ₩183,100 ₩-23.1bn ₩-22.3bn +₩37.1bn
2026-09-07 ₩186,300 ₩-32.2bn ₩-0.9bn +₩25.5bn
2026-09-04 ₩188,100 ₩-15.8bn +₩11.8bn ₩-4.3bn
2026-09-03 ₩187,100 ₩-6.9bn +₩10.8bn ₩-12.5bn
2026-09-02 ₩186,300 +₩3.9bn ₩-9.3bn ₩-3.6bn
2026-09-01 ₩188,000 ₩-5.7bn ₩-11.0bn +₩7.8bn
2026-08-31 ₩188,900 ₩-10.2bn ₩-2.0bn +₩9.2bn
2026-08-28 ₩190,700 ₩-9.3bn ₩-0.0bn +₩9.1bn
2026-08-27 ₩191,300 ₩-11.9bn ₩-3.4bn +₩14.8bn
2026-08-26 ₩193,400 +₩7.3bn +₩15.5bn ₩-23.3bn
2026-08-25 ₩189,600 ₩-17.6bn +₩0.9bn +₩16.5bn
2026-08-24 ₩194,000 ₩-6.6bn +₩14.8bn ₩-8.0bn
2026-08-21 ₩192,300 ₩-3.9bn +₩7.3bn ₩-4.4bn
2026-08-20 ₩194,100 +₩13.1bn ₩-26.9bn +₩13.5bn
2026-08-19 ₩194,100 +₩0.6bn ₩-6.7bn +₩6.0bn
2026-08-18 ₩195,500 +₩17.8bn ₩-20.1bn +₩3.1bn
2026-08-14 ₩201,000 +₩18.6bn ₩-10.8bn ₩-10.1bn
2026-08-13 ₩202,000 +₩37.7bn ₩-37.4bn +₩1.1bn
2026-08-12 ₩202,000 ₩-4.5bn ₩-32.3bn +₩42.3bn
2026-08-11 ₩210,500 +₩132.4bn +₩11.7bn ₩-140.3bn
2026-08-10 ₩201,000 +₩39.9bn ₩-0.1bn ₩-38.8bn
2026-08-07 ₩199,300 +₩29.5bn +₩33.0bn ₩-61.5bn
2026-08-06 ₩195,000 +₩20.5bn +₩32.6bn ₩-57.6bn
2026-08-05 ₩190,300 +₩42.0bn +₩6.0bn ₩-47.4bn
2026-08-04 ₩185,800 +₩28.9bn ₩-10.5bn ₩-17.7bn
2026-08-03 ₩182,200 ₩-9.2bn ₩-18.0bn +₩27.5bn
2026-07-31 ₩186,700 ₩-12.6bn ₩-46.4bn +₩58.3bn
2026-07-30 ₩190,000 +₩13.4bn +₩70.0bn ₩-83.3bn
2026-07-29 ₩180,000 ₩-32.7bn +₩55.1bn ₩-54.9bn
2026-07-28 ₩177,400 ₩-25.9bn +₩76.0bn ₩-49.7bn
2026-07-27 ₩178,700 ₩-16.4bn +₩27.5bn ₩-11.8bn
2026-07-24 ₩177,600 +₩29.2bn +₩30.0bn ₩-58.2bn
2026-07-23 ₩172,200 +₩16.5bn ₩-4.9bn ₩-10.3bn
2026-07-22 ₩170,100 +₩13.3bn ₩-5.8bn ₩-7.6bn
2026-07-21 ₩171,600 +₩9.0bn +₩1.3bn ₩-10.1bn
2026-07-20 ₩172,600 ₩-5.5bn +₩4.7bn +₩2.0bn
2026-07-16 ₩175,800 +₩11.3bn +₩1.1bn ₩-12.4bn
2026-07-15 ₩175,700 +₩25.2bn ₩-11.9bn ₩-13.9bn
2026-07-14 ₩172,800 +₩4.1bn +₩18.5bn ₩-23.2bn
2026-07-13 ₩175,100 +₩19.8bn +₩24.4bn ₩-43.9bn

Investor flows summary

Window Foreign (USD) Institutions Retail
1 day ₩-4.8bn $-4M +₩19.0bn ₩-23.0bn
5 days ₩-11.4bn $-9M +₩10.6bn ₩-43.7bn
20 days +₩30.4bn +$23M ₩-81.6bn ₩-59.5bn

Positive = net buying, negative = net selling. Values aggregate the KRX main board and the NXT alternative venue.

Frequently asked questions

Are foreign investors buying Celltrion stock?

Over the last 5 sessions foreign investors net sold ₩11.4bn ($9M) of Celltrion; over 60 sessions they net bought ₩295.4bn ($222M); since Jan 1, 2026 they net bought ₩1,866.0bn ($1.4B). Over 20 sessions the stock is the 25th largest foreign net purchase among 832 KOSPI stocks.

How much of Celltrion do foreign investors own?

Foreign investors own 25.29% of Celltrion's shares as of Oct 13, 2026, versus 21.26% one year earlier. The figure is KRX's daily foreign holdings divided by listed shares, and it reflects trades settled through the previous session.

Who is on the other side — institutions or retail investors?

Over 20 sessions institutions net sold ₩81.6bn ($61M) and retail investors net sold ₩59.5bn ($45M) of Celltrion. Foreign buying is being met mainly by retail selling.

Is Celltrion listed on KOSPI or KOSDAQ?

Celltrion (셀트리온) trades on KOSPI under KRX code 068270 in the Biotech & Pharma group, with a market capitalization of ₩42T ($31.4B). Daily net flows by investor type are published by KRX after each session and combine the KRX main board with the NXT venue.

Annual financials

Fiscal year Revenue YoY Operating profit Net income
2023 ₩2.2T ($1.6B) – ₩651bn ($489M) ₩540bn ($405M)
2024 ₩3.6T ($2.7B) +63.40% ₩492bn ($369M) ₩419bn ($314M)
2025 ₩4.2T ($3.1B) +17.00% ₩1.2T ($877M) ₩1.0T ($774M)

Consolidated (K-IFRS) where available, from DART regulatory filings. USD figures converted at the current rate (₩1333.09/$) for reference only.

← All foreign investor flows